Cancer nanomedicine meets immunotherapy: opportunities and challenges

Qingxue Sun, Xiangyang Bai, Alexandros Marios Sofias, Roy van der Meel, Eduardo Ruiz-Hernandez, Gert Storm, Wim E. Hennink, Bruno De Geest, F. Kiessling, Hai-jun Yu, Twan Lammers (Corresponding author), Yang Shi (Corresponding author)

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

5 Citaten (Scopus)

Samenvatting

Cancer nanomedicines have shown promise in combination immunotherapy, thus far mostly preclinically but also already in clinical trials. Combining nanomedicines with immunotherapy aims to reinforce the cancer-immunity cycle, via potentiating key steps in the immune reaction cascade, namely antigen release, antigen processing, antigen presentation, and immune cell-mediated killing. Combination nano-immunotherapy can be realized via three targeting strategies, i.e., by targeting cancer cells, targeting the tumor immune microenvironment, and targeting the peripheral immune system. The clinical potential of nano-immunotherapy has recently been demonstrated in a phase III trial in which nano-albumin paclitaxel (Abraxane®) was combined with atezolizumab (Tecentriq®) for the treatment of patients suffering from advanced triple-negative breast cancer. In the present paper, besides strategies and initial (pre)clinical success stories, we also discuss several key challenges in nano-immunotherapy. Taken together, nanomedicines combined with immunotherapy are gaining significant attention, and it is anticipated that they will play an increasingly important role in clinical cancer therapy.
Originele taal-2Engels
Pagina's (van-tot)954-958
Aantal pagina's5
TijdschriftActa Pharmacologica Sinica
Volume41
Nummer van het tijdschrift7
Vroegere onlinedatum17 jun 2020
DOI's
StatusGepubliceerd - jul 2020

Vingerafdruk Duik in de onderzoeksthema's van 'Cancer nanomedicine meets immunotherapy: opportunities and challenges'. Samen vormen ze een unieke vingerafdruk.

Citeer dit